David Toung
Stock Analyst at Argus Research
(4.13)
# 459
Out of 5,161 analysts
132
Total ratings
62.75%
Success rate
9.08%
Average return
Main Sectors:
Stocks Rated by David Toung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Upgrades: Buy | $35 | $26.86 | +30.31% | 2 | Mar 2, 2026 | |
| HCA HCA Healthcare | Maintains: Buy | $530 → $560 | $532.58 | +5.15% | 3 | Feb 6, 2026 | |
| HOLX Hologic | Downgrades: Hold | n/a | $75.21 | - | 3 | Jan 12, 2026 | |
| TECH Bio-Techne | Maintains: Buy | $65 → $68 | $51.47 | +32.12% | 4 | Nov 20, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $580 → $610 | $475.89 | +28.18% | 8 | Oct 29, 2025 | |
| MDT Medtronic | Maintains: Buy | $105 → $115 | $87.38 | +31.61% | 7 | Aug 26, 2025 | |
| HUM Humana | Reiterates: Hold | $282 | $163.67 | +72.29% | 9 | Aug 14, 2025 | |
| ELV Elevance Health | Downgrades: Hold | n/a | $287.89 | - | 4 | Jul 21, 2025 | |
| GFS GLOBALFOUNDRIES | Initiates: Buy | $52 | $41.59 | +25.03% | 1 | Jul 1, 2025 | |
| UNH UnitedHealth Group | Downgrades: Hold | n/a | $277.05 | - | 8 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $9.17 | - | 2 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $225.37 | - | 6 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $125 | $219.09 | -42.95% | 9 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $152.66 | - | 5 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $340 | $367.79 | -7.56% | 10 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $570 → $670 | $944.36 | -29.05% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $150 | $92.59 | +62.00% | 7 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $770 → $840 | $977.25 | -14.04% | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $110 | $70.33 | +56.41% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $262.91 | - | 1 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $310 | $337.21 | -8.07% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $265 → $320 | $479.27 | -33.23% | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $135 | $108.14 | +24.84% | 4 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $75 | $145.21 | -48.35% | 5 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $58.95 | - | 4 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $110 | $115.91 | -5.10% | 3 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.36 | - | 1 | Aug 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $192.50 | - | 4 | Apr 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $154.25 | - | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $165 → $155 | $242.04 | -35.96% | 4 | Mar 27, 2020 |
Pfizer
Mar 2, 2026
Upgrades: Buy
Price Target: $35
Current: $26.86
Upside: +30.31%
HCA Healthcare
Feb 6, 2026
Maintains: Buy
Price Target: $530 → $560
Current: $532.58
Upside: +5.15%
Hologic
Jan 12, 2026
Downgrades: Hold
Price Target: n/a
Current: $75.21
Upside: -
Bio-Techne
Nov 20, 2025
Maintains: Buy
Price Target: $65 → $68
Current: $51.47
Upside: +32.12%
Thermo Fisher Scientific
Oct 29, 2025
Maintains: Buy
Price Target: $580 → $610
Current: $475.89
Upside: +28.18%
Medtronic
Aug 26, 2025
Maintains: Buy
Price Target: $105 → $115
Current: $87.38
Upside: +31.61%
Humana
Aug 14, 2025
Reiterates: Hold
Price Target: $282
Current: $163.67
Upside: +72.29%
Elevance Health
Jul 21, 2025
Downgrades: Hold
Price Target: n/a
Current: $287.89
Upside: -
GLOBALFOUNDRIES
Jul 1, 2025
Initiates: Buy
Price Target: $52
Current: $41.59
Upside: +25.03%
UnitedHealth Group
Apr 21, 2025
Downgrades: Hold
Price Target: n/a
Current: $277.05
Upside: -
Mar 31, 2025
Upgrades: Buy
Price Target: n/a
Current: $9.17
Upside: -
Nov 4, 2024
Upgrades: Buy
Price Target: n/a
Current: $225.37
Upside: -
Sep 11, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $219.09
Upside: -42.95%
Jun 28, 2024
Downgrades: Hold
Price Target: n/a
Current: $152.66
Upside: -
Jun 27, 2024
Maintains: Buy
Price Target: $300 → $340
Current: $367.79
Upside: -7.56%
Jun 24, 2024
Maintains: Buy
Price Target: $570 → $670
Current: $944.36
Upside: -29.05%
May 21, 2024
Upgrades: Buy
Price Target: $150
Current: $92.59
Upside: +62.00%
May 14, 2024
Maintains: Buy
Price Target: $770 → $840
Current: $977.25
Upside: -14.04%
Apr 1, 2024
Maintains: Buy
Price Target: $80 → $110
Current: $70.33
Upside: +56.41%
Mar 25, 2024
Upgrades: Buy
Price Target: n/a
Current: $262.91
Upside: -
May 25, 2023
Maintains: Buy
Price Target: $285 → $310
Current: $337.21
Upside: -8.07%
Dec 22, 2022
Maintains: Buy
Price Target: $265 → $320
Current: $479.27
Upside: -33.23%
Jul 28, 2022
Maintains: Buy
Price Target: $150 → $135
Current: $108.14
Upside: +24.84%
Jan 28, 2022
Upgrades: Buy
Price Target: $75
Current: $145.21
Upside: -48.35%
Nov 1, 2021
Downgrades: Hold
Price Target: n/a
Current: $58.95
Upside: -
Nov 1, 2021
Upgrades: Buy
Price Target: $110
Current: $115.91
Upside: -5.10%
Aug 2, 2021
Downgrades: Hold
Price Target: n/a
Current: $5.36
Upside: -
Apr 12, 2021
Downgrades: Hold
Price Target: n/a
Current: $192.50
Upside: -
Mar 10, 2021
Downgrades: Hold
Price Target: n/a
Current: $154.25
Upside: -
Mar 27, 2020
Reiterates: Buy
Price Target: $165 → $155
Current: $242.04
Upside: -35.96%